Integrating AI, RNA Vaccines, and CAR‐T Cells for Personalized Treatment
Abstract
Oncology is undergoing a profound transformation driven by the convergence of artificial intelligence (AI), RNA‐based vaccines, and chimeric antigen receptor T‐cell (CAR‐T) therapies. Individually, these technologies have advanced cancer diagnosis, treatment, and patient stratification. AI‐driven approaches enhance drug discovery, optimize clinical trial design, and enable personalized therapeutic decision‐making. RNA vaccines provide a flexible platform for encoding tumor‐specific neoantigens, while CAR‐T therapies enable targeted immune‐mediated tumor cell elimination. Early‐phase clinical trials, particularly those combining RNA vaccines with immune checkpoint inhibitors, have demonstrated promising improvements in recurrence‐free survival (RFS) and immunogenicity. However, evidence supporting direct combinations of RNA vaccines and CAR‐T therapies remains largely preclinical or limited to early‐phase investigation and should therefore be interpreted with caution. This review explores how AI facilitates neoantigen discovery, RNA vaccine optimization, and CAR‐T cell engineering, and examines the emerging interplay between these modalities. While their integration represents a compelling framework for personalized oncology, significant challenges remain, including clinical validation, scalability, regulatory oversight, and equitable access.
Related
- Personalized Cardiac Rehabilitation: Integrating Biomarker-Guided, Technology-Enabled, and Population-Specific Strategies in Exercise Medicine.
- Personalized Therapeutic Strategies in Glioblastoma: Bridging Molecular Markers and In Vivo Observations for Targeted Treatment
- Genetic Predictors of Curve Progression and Brace Treatment Response in Adolescent Idiopathic Scoliosis: Toward Personalized Management
- Personalized Management of Hydrosalpinx Before IVF: A Narrative Review of Reproductive Outcomes and Treatment Timing
- Feasibility and engagement of smartphone delivered yoga imagery with or without personalized avatars in residential substance use treatment: The AT-REACH nonrandomized pilot
BibTeX
@article{haykal2026integrating,
title = {{Integrating AI, RNA Vaccines, and CAR‐T Cells for Personalized Treatment}},
author = {Diala Haykal and Brigitte Dréno},
journal = {Journal of Immunology Research},
year = {2026},
month = sep,
doi = {10.1155/jimr/2275385},
url = {https://inserm.hal.science/inserm-05736723v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Integrating AI, RNA Vaccines, and CAR‐T Cells for Personalized Treatment
AU - Diala Haykal
AU - Brigitte Dréno
PY - 2026
DA - 2026/09/01
JO - Journal of Immunology Research
DO - 10.1155/jimr/2275385
UR - https://inserm.hal.science/inserm-05736723v1
AB - Oncology is undergoing a profound transformation driven by the convergence of artificial intelligence (AI), RNA‐based vaccines, and chimeric antigen receptor T‐cell (CAR‐T) therapies. Individually, these technologies have advanced cancer diagnosis, treatment, and patient stratification. AI‐driven approaches enhance drug discovery, optimize clinical trial design, and enable personalized therapeutic decision‐making. RNA vaccines provide a flexible platform for encoding tumor‐specific neoantigens, while CAR‐T therapies enable targeted immune‐mediated tumor cell elimination. Early‐phase clinical trials, particularly those combining RNA vaccines with immune checkpoint inhibitors, have demonstrated promising improvements in recurrence‐free survival (RFS) and immunogenicity. However, evidence supporting direct combinations of RNA vaccines and CAR‐T therapies remains largely preclinical or limited to early‐phase investigation and should therefore be interpreted with caution. This review explores how AI facilitates neoantigen discovery, RNA vaccine optimization, and CAR‐T cell engineering, and examines the emerging interplay between these modalities. While their integration represents a compelling framework for personalized oncology, significant challenges remain, including clinical validation, scalability, regulatory oversight, and equitable access.
SN - 2314-8861
SN - 2314-7156
ER -